Bayer CropScience (506285) Q4 2004 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2004 earnings summary
19 Oct, 2026Executive summary
FY2004 results reflect a narrower crop-science portfolio after non-crop businesses were carved out; standalone turnover was Rs 8,244.54 million and profit after tax Rs 263.61 million.
Consolidated profit before tax rose to Rs 606.773 million from Rs 472.577 million, while profit after tax was Rs 314.532 million versus Rs 327.676 million.
Financial highlights
Consolidated net sales were Rs 8,047.776 million versus Rs 8,685.134 million; total income was Rs 8,461.974 million versus Rs 9,012.265 million.
Adjusted for prior-period and extraordinary items, consolidated PBT was Rs 565.196 million versus Rs 810.383 million; adjusted after-tax profit was Rs 302.615 million versus Rs 520.749 million.
Consolidated profit after tax was Rs 314.532 million; proposed dividend remained Rs 2.20 per Rs 10 share, or 22%, absorbing Rs 86.90 million.
Outlook and guidance
FY2005 crop-protection performance expected to depend on normal, well-distributed rainfall; four new product registrations were expected to add revenue from new crop-pest segments.
Environmental Science planned further launches in Vector Control and Professional Pest Control, with marketing and support focused on PPC growth while sustaining VC share.
Latest events from Bayer CropScience
- CropScience scale expanded through merger, while one-offs weighed on reported earnings.506285
Q4 2003 - Drought drove a sharp earnings decline, while export and specialty-business growth offered offsets.506285
Q4 2002 - PAT rose 41% as market share advanced to 16% despite a 12% industry decline.506285
Q4 2005 - Profit rose as new products and seed distribution broadened growth plans; Thane closures triggered impairment.506285
Q4 2006 - 15-month PAT was Rs 491m; Thane restructuring costs offset investment-sale gains.506285
Q4 07/08 - PAT reached Rs. 944.59 million as new products met rising crop-protection demand.506285
Q4 08/09 - Sales and PAT rose as new launches supported growth amid pricing and operational risks.506285
Q4 09/10 - Revenue advanced and PAT grew modestly as innovation-led expansion met pricing and regulatory risks.506285
Q4 10/11 - Revenue and PAT rose despite a ₹579m Thane remediation charge.506285
Q4 11/12